EZH2 and neoplasm: We next treated RB1 non-mutated tumor cells with 10 μM GSK503 for 72 h and found that the binding of EZH2 to the RB1 promoter was abolished, which led to a decrease in H3K27me3 in the RB1 promoter (Fig. 5A, B).